Single article

DOI: 10.47026/2413-4864-2023-2-124-138
Full article

UDC: 616.895-02:616.441-008.64-085.214
BBC: Р415.21-527.02+Р64-52

Nikolaev E.E., Golenkov A.V., Madyanov I.V.

The use of lithium medications in psychiatric practice in the context of their effect on the thyroid status

Keywords: lithium, thyroid gland, hypothyroidism, goiter, bipolar affective disorder

Lithium has a wide range of beneficial pharmacological effects and is practically a single option drug in some patients with bipolar affective disorder. At the same time, lithium can cause changes in the structure and function of the thyroid gland. Hypothyroidism and goiter are the most common thyroid disorders in patients receiving long-term lithium therapy. Hence, psychiatrists may have doubts about the safety of administering lithium to patients with thyroid pathology. Additional difficulties may arise when a patient is found to have lithium-induced thyroid disorders. This topic is not sufficiently covered in domestic manuals on psychiatry. That is why the purpose of this article is to review modern literature sources on the effect of lithium on the thyroid gland, recommendations for monitoring lithium-induced thyroid disorders and ways to correct the developing pathology. The article discusses possible mechanisms of disorders in the structure and functioning of the thyroid gland during lithium treatment. Literature data on the influence of gender, ethnicity and duration of lithium therapy on the development of thyroid pathology are presented. The article presents the algorithm for the safe use of lithium medications in the aspect of thyroid pathology. If the thyroid function is slightly reduced during the initial examination, lithium can be prescribed if necessary, but hypothyroidism should be treated with sodium levothyroxine. In the presence of difficult-to-correct hypothyroidism, it is recommended to choose another mood stabilizing agent. Lithium preparations are the most important component in the complex treatment of bipolar affective disorder. Withholding therapy due to the developed thyroid pathology, which is well corrected with medications and more often has a transient character, is not justified. For safe lithium treatment, it is important to monitor the main parameters of the thyroid gland in a timely manner before and during therapy.

References

  1. Avrutskii G.Ya., Neduva A.A. Lechenie psikhicheski bol‘nykh: rukovodstvo dlya vrachei. 2-e izd., pererab. i dop. [Treatment of the mentally ill: a guide for physicians. 2nd]. Moscow, Meditsina Publ., 1988, 528 p.
  2. Aleksandrovskii Yu.A., Neznanov N.G., eds., Aleksandrovskii Yu.A. Ratsional’naya farmakoterapiya v psikhiatricheskoi praktike: rukovodstvo dlya praktikuyushchikh vrachei [Rational pharmacotherapy in psychiatric practice: a guide for practitioners]. Moscow, Litterra Publ., 2014, 1080 p.
  3. Arana G., Rozenbaum J. Handbook of Psychiatric Drug Therapy, Lippincott Williams & Wilkins, 2001 (Russ. ed.: Farmakoterapiya psikhicheskikh rasstroistv. Moscow, Izdatel’stvo BINOM Publ., 2004. 416 p.).
  4. Gosudarstvennyi reestr lekarstvennykh sredstv. Litiya karbonat [Russian State register of medicines. Lithium carbonate]. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4f729b28-c003-43aa-b380-502708e765ec (Accessed 1 December 2022).
  5. Troshina E.A., Panfilova E.A., Mikhina M.S. et al. Klinicheskie rekomendatsii “Ostrye i khronicheskie tireoidity (isklyuchaya autoimmunnyi tireoidit)” [Clinical guidelines “Acute and chronic thyroiditis (excluding autoimmune thyroiditis)”]. Problemy endokrinologii, 2021, vol. 67(2), pp. 57–83.
  6. Mazo G.E., Gorobets L.N. Strategiya augmentatsii kak odin iz vidov kombinirovannoi terapii u bol’nykh s depressivnymi rasstroistvami (litii i tireoidnye gormony) [Augmentation strategy as one of the types of combination therapy in patients with depressive disorders (lithium and thyroid hormones)]. Sotsial’naya i klinicheskaya Psikhiatriya, 2020, vol. 30(2), pp. 52–61.
  7. Malin D.I. Pobochnoe deistvie psikhotropnykh sredstv [Side effects of psychotropic drugs]. Moscow, Vuzovskaya kniga Pub., 20, 208 p.
  8. Matsueva I.A., Dalmatova A.B., Andreichenko T.V., Grineva E.N. Lechenie tireotoksikoza karbonatom litiya. Sluchai iz praktiki [Treatment of thyrotoxicosis with lithium carbonate. Cases from practice]. Klinicheskaya i eksperimental’naya tireoidologiya, 2021, vol. 17(3), pp. 22–26.
  9. Stahl S. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, Cambridge University Press, 2021 (Russ. ed.: Osnovy psikhofarmakologii. Teoriya i praktika. Moscow, GEOTAR-Media Publ., 2022. 656 p.).
  10. Schatzberg A.F., DeBattista Ch. Schatzberg’s manual of clinical psychopharmacology, American Psychiatric Association, 2019 (Russ ed.: Rukovodstvo po klinicheskoi psikhofarmakologii Shatsberga. Moscow, MEDpress-inform Publ., 2022, 672 p.).
  11. Ahmadi-AbhariA., Ghaeli P., Fahimi F., Esfahanian F. et al. Risk factors of thyroid abnormalities in bipolar patients receiving lithium: a case control study. BMC Psychiatry, 2003, vol. 3, pp. 1–5. DOI: 10.1186/1471-244X-3-4.
  12. Ahmed I., Ma V., Liu Y., Khan M.S. et al. Lithium from breast-milk inhibits thyroid iodine uptake and hormone production, which are remedied by maternal iodine supplementation. Bipolar Disord., 2021, vol. 23(6), pp. 615– DOI: 10.1111/bdi.13047.
  13. Baethge C., Blumentritt H., Berghöfer A., Bschor T. et al. Long-term lithium treatment and thyroid antibodies: a controlled study. J Psychiatry Neurosci., 2005, vol. 30(6), pp. 423–
  14. Barbesino G. Drugs affecting thyroid function. Thyroid, 2010, vol. 20(7), pp. 763–770. DOI: 10.1089/thy.2010.1635.
  15. Bauer M., Blumentritt H., Finke R., Schlattmann P. et al. Using ultrasonography to determine thyroid size and prevalence of goiter in lithium-treated patients with affective disorders. J Affect Disord., 2007, vol. 104(1-3), pp. 45– DOI: 10.1016/j.jad.2007.01.033.
  16. Bennie E.H., Lazarus J.H. Lithium-induced thyroid dysfunction. Lancet, 1972, vol. 300, pp. 44–4 DOI: 10.1016/s0140-6736(72)91302-5.
  17. Bocchetta A., Cocco F., Velluzzi F., Del Zompo M. et al. Fifteen-year follow-up of thyroid function in lithium patients. J Endocrinol Invest., 2007, vol. 30(5), pp. 363–366. DOI: 10.1007/BF03346311.
  18. Bocchetta A., Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemiol Ment Health, 2006, vol. 2, pp. 1–5. DOI: 10.1186/1745-0179-2-23.
  19. Broberg K., Concha G., Engström K. et al. Lithium in drinking water and thyroid function. Environ Health Perspect., 2011, vol. 119(6), pp. 827–8 DOI: 10.1289/ehp.1002678.
  20. Brownlie B.E., Turner J.G. Lithium associated thyrotoxicosis. Clin Endocrinol (Oxf), 2011, vol. 75(3), pp. 402–403. Doi: 10.1111/j.1365-2265.2011.04048.x.
  21. Cade J.F. Lithium salts in the treatment of psychotic excitement. Med J Aust., 1949, vol. 2(10), pp. 349–52. DOI: 10.1080/j.1440-1614.1999.06241.x.
  22. Czarnywojtek A., Zgorzalewicz-Stachowiak M., Czarnocka B. et al. Effect of lithium carbonate on the function of the thyroid gland: mechanism of action and clinical implications. J Physiol Pharmacol., 2020, vol. 71(2), pp. 191–199. DOI: 10.26402/jpp.2020.2.03.
  23. Draaisma D. Lithium: the gripping history of a psychiatric success story. Nature, 2019, vol. 572, pp. 584– DOI: 10.1038/d41586-019-02480-0.
  24. Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord, 2016, vol. 4, pp. 1–10. DOI: 10.1186/s40345-016-0068-y.
  25. Haggerty J.J.Jr., Silva S.G., Marquardt M. et al. Prevalence of antithyroid antibodies in mood disorders. Depress Anxiety, 1997, vol. 5(2), pp. 91–96.
  26. Haissaguerre M., Vantyghem M.C. What an endocrinologist should know for patients receiving lithium therapy. Ann Endocrinol (Paris), 2022, vol. 83(4), pp. 219– DOI: 10.1016/j.ando.2022.01.001.
  27. Kessler L., Palla J., Baru J.S., Onyenwenyi C., George A.M., Lucas B.P. Lithium as an adjunct to radioactive iodine for the treatment of hyperthyroidism: a systematic review and meta-analysis. Endocr Pract., 2014, vol. 20(7), pp. 737–7 DOI: 10.4158/EP13504.RA.
  28. Kibirige D., Luzinda K., Ssekitoleko R. Spectrum of lithium induced thyroid abnormalities: a current perspective. Thyroid Res., 2013, vol. 6(1), pp. 1–5. DOI:10.1186/1756-6614-6-3.
  29. Kirov G., Tredget J., John R. et al. A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord., 2005, vol. 87(2-3), pp. 313– DOI: 10.1016/j.jad.2005.03.010.
  30. Kraszewska A., Abramowicz M., Chłopocka-Woźniak M. et al. The effect of lithium on thyroid function in patients with bipolar disorder. Psychiatr Pol., 2014, vol. 48(3), pp. 417–4
  31. Kraszewska A., Chlopocka-Wozniak M., Abramowicz M. et al. A cross-sectional study of thyroid function in 66 patients with bipolar disorder receiving lithium for 10-44 years. Bipolar Disord., 2015, vol. 17(4), pp. 375–3 DOI: 10.1111/bdi.12275.
  32. Kraszewska A., Ziemnicka K., Jończyk-Potoczna K. et al. Thyroid structure and function in long-term lithium-treated and lithium-naïve bipolar patients. Hum Psychopharmacol., 2019, vol. 34(4), p. 2708. DOI: 10.1002/hup.2708.
  33. Kraszewska A., Ziemnicka K., Sowiński J. et al. No Connection between Long-Term Lithium Treatment and Antithyroid Antibodies. Pharmacopsychiatry, 2019, vol. 52(5), pp. 232–236. DOI: 10.1055/a-0838-6062.
  34. Lazarus J.H., Bennie E.H. Effect of lithium on thyroid function in man. Acta Endocrinol (Copenh), 1972, vol. 70(2), pp. 266–2 DOI: 10.1530/acta.0.0700266.
  35. Lazarus J.H., John R., Bennie E.H. et al. Lithium therapy and thyroid function: a long-term study. Psychol Med., 1981, vol. 11(1), pp. 85– DOI: 10.1017/s0033291700053307.
  36. Lazarus J.H., Richards A.R., Addison G.M., Owen G.M. Treatment of thyrotoxicosis with lithium carbonate. Lancet, 1974, vol. 304, pp. 1160– DOI: 10.1016/s0140-6736(74)90808-3.
  37. Lazarus J.H. Is thyroxine during lithium therapy necessary? J Endocrinol Invest., 1998, vol. 21(11), pp. 784–78 DOI: 10.1007/BF03348047.
  38. Lazarus J.H. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab., 2009, vol. 23(6), pp. 723–7 DOI: 10.1016/j.beem.2009.06.002.
  39. Lazarus J.H. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid, 1998, vol. 8(10), pp. 909– DOI: 10.1089/thy.1998.8.909.
  40. Lee S., Chow C.C., Wing Y.K. et al. Thyroid function and psychiatric morbidity in patients with manic disorder receiving lithium therapy. J Clin Psychopharmacol. 2000, vol. 20(2), pp. 204– DOI: 10.1097/00004714-200004000-00013.
  41. Lee S., Chow C.C., Wing Y.K., Shek C.C. Thyroid abnormalities during chronic lithium treatment in Hong Kong Chinese: a controlled study. J Affect Disord., 1992, vol. 26(3):, vol. 173– DOI: 10.1016/0165-0327(92)90013-v.
  42. Lerena V.S., León N.S., Sosa S. et al. Lithium and endocrine dysfunction. Medicina (B Aires), 2022, vol. 82(1), pp. 130–
  43. Lieber I., Ott M., Öhlund L. et al. Lithium-associated hypothyroidism and potential for reversibility after lithium discontinuation: Findings from the LiSIE retrospective cohort study. J Psychopharmacol., 2020, vol. 34(3), pp. 293–303. DOI: 10.1177/0269881119882858.
  44. Loviselli A., Bocchetta A., Mossa P. et al. Value of thyroid echography in the long-term follow-up of lithium-treated patients. Neuropsychobiology, 1997, vol, 36(1), pp. 37– DOI: 10.1159/000119358.
  45. McKnight R.F., Adida M., Budge K. et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet, 2012, vol. 379, pp. 721– DOI: 10.1016/S0140-6736(11)61516-X.
  46. Mizukami Y., Michigishi T., Nonomura A. et al. Histological features of the thyroid gland in a patient with lithium induced thyrotoxicosis. J Clin Pathol., 1995, vol. 48(6), pp. 582–
  47. Ozsoy S., Mavili E., Aydin M., Turan T., Esel E. Ultrasonically determined thyroid volume and thyroid functions in lithium-naïve and lithium-treated patients with bipolar disorder: a cross-sectional and longitudinal study. Hum Psychopharmacol., 2010, vol. 25(2), pp. 174–17 DOI: 10.1002/hup.1093.
  48. Płazińska M.T., Królicki L., Bąk M. Lithium carbonate pre-treatment in 131-I therapy of hyperthyroidism. Nucl Med Rev Cent East Eur., 2011, vol. 14(1), pp. 3– DOI: 10.5603/nmr.2011.0002.
  49. Rao A.S., Kremenevskaja N., Resch J., Brabant G. Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/beta-catenin signalling. Eur J Endocrinol., 2005, vol. 153(6), pp. 929–938. DOI: 10.1530/eje.1.02038.
  50. Samareh F.H., Pishnamaz S.F., Jafari E. et al. Investigating the protective role of metformin on lithium-induced hypothyroidism. J Biochem Mol Toxicol., 2022, vol. 36(3), pp. 22977. DOI: 10.1002/jbt.22977.
  51. Schou M., Amdisen A., Eskjaer J.S., Olsen T. Occurrence of goitre during lithium treatment. Br Med J., 1968, vol. 3, pp. 710– DOI: 10.1136/bmj.3.5620.710.
  52. Sethy R.R., Sinha V.K. Effect of lithium on thyroid function in adolescents with mood disorder. Asian J Psychiatr., 2016, vol. 24, pp. 41– DOI: 10.1016/j.ajp.2016.08.004.
  53. Surks M.I., Ross D.S., Mulder J.E. Lithium and the thyroid. Available at: https://pro.uptodatefree.ir/show/7843.
  54. Tondo L., Baldessarini R.J. Antisuicidal Effects in Mood Disorders: Are They Unique to Lithium? Pharmacopsychiatry, 2018, vol. 51(5), pp. 177–188. DOI: 10.1055/a-0596-7853.
  55. Urabe M., Hershman J.M., Pang X.P. et al. Effect of lithium on function and growth of thyroid cells in vitro. Endocrinology, 1991, vol. 129(2), pp. 807– DOI: 10.1210/endo-129-2-807.
  56. Walshaw P.D., Gyulai L., Bauer M. et al. Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double-blind placebo-controlled trial of levothyroxine (L-T4) and triiodothyronine (T3). Bipolar Disord., 2018, vol. 20(7), pp. 594– DOI: 10.1111/bdi.12657.
  57. Yamazaki C.A., Padovani R.P., Biscolla R.P. et al. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma. Thyroid, 2012, vol. 22(10), pp. 1002– DOI: 10.1089/thy.2011.0372.
  58. Zaki S.M., Hussein G.H.A., Helal G.M. et al. Green tea extract modulates lithium-induced thyroid follicular cell damage in rats. Folia Morphol (Warsz), 2022, vol. 81(3), pp. 594– DOI: 10.5603/FM.a2021.0052.

About authors

Nikolaev Egor E.
Resident, Department of Psychiatry, Medical Psychology and Neurology, Chuvash State University, Russia, Cheboksary (nikegev@bk.ru; ORCID: https://orcid.org/0000-0002-2774-4443)
Golenkov Andrey V.
Doctor of Medical Sciences, Professor, Department of Psychiatry, Medical Psychology and Neurology, Chuvash State University, Russia, Cheboksary (golenkovav@inbox.ru; ORCID: https://orcid.org/0000-0002-3799-0736)
Madyanov Igor V.
Doctor of Medical Sciences, Professor, Department of Therapy and Family Medicine, Institute of Advanced Medical Training;Professor, Department of Faculty and Hospital Therapy, Chuvash State University, Russia, Cheboksary (igo-madyanov@yandex.ru; ORCID: https://orcid.org/0000-0001-8750-2799)

Article link

Nikolaev E.E., Golenkov A.V., Madyanov I.V. The use of lithium medications in psychiatric practice in the context of their effect on the thyroid status [Electronic resource] // Acta medica Eurasica. – 2023. – №2. P. 124-138. – URL: https://acta-medica-eurasica.ru/en/single/2023/2/12/. DOI: 10.47026/2413-4864-2023-2-124-138.

Menu

Journal numbers

Archive for year 2024
Archive for year 2023
Archive for year 2022
Archive for year 2021
Archive for year 2020
Archive for year 2019
Archive for year 2018
Archive for year 2017
Archive for year 2016
Archive for year 2015